Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043329 | 0.85 | KISS1R (0.38) | KISS1RIKBKBCDK2KDM1AHDAC1 | |
| SCHEMBL14418774 | 0.85 | FYN (0.41) | KISS1RGSK3BFYN | |
| SCHEMBL12954206 | 0.85 | ALDH1A1 (0.44) | HDAC1 | |
| SCHEMBL14418842 | 0.81 | KDM1A (0.43) | CDK2KDM1AHDAC1GSK3B | |
| SCHEMBL14581427 | 0.81 | POLB (0.47) | — | |
| SCHEMBL14613372 | 0.80 | HDAC1 (0.41) | CDK2KDM1AHDAC1GSK3B | |
| SCHEMBL14613373 | 0.79 | EPHX2 (0.44) | CDK2EPHX2HDAC1GSK3B | |
| SCHEMBL14613482 | 0.79 | GSK3B (0.42) | CDK2GSK3B | |
| SCHEMBL14545970 | 0.78 | GSK3B (0.45) | CDK2HDAC1GSK3B | |
| SCHEMBL14545261 | 0.78 | CDK2 (0.53) | CDK2EPHX2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CSNK2A1 133/4885KISS1R 2135/4885IKBKB 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.